Snow Ellen
Known title: SVP, CFO and TreasurerCIK: 0001786643
Associated companies
Transaction History
| AKBA | ▲ Buy | Grant | 149,300 | $0 | 1/31/2024 | View on chart |
| AKBA | ▲ Buy | Grant | 370,000 | $0 | 7/31/2023 | View on chart |
| AKBA | ▲ Buy | Grant | 149,300 | $0 | 1/31/2024 | View on chart |
| AKBA | ▲ Buy | Grant | 370,000 | $0 | 7/31/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
AKBA sees no direct news updates this week
In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.
AKBA sees no direct news updates this week. In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.